TNGXTango Therapeutics, Inc.Signing up patients
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Locally Advanced Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 225 (planned)
- Started
- May 26, 2023
- Main results expected
- Jun 2027
- Fully finished
- Jun 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1 Maximum Tolerated Dose
Measured over: 28 days and 21 days
Phase 1 Dosing Schedule
Measured over: 28 days
Phase 2 Anti-neoplastic Activity
Measured over: 16 weeks and 18 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05732831 · record last updated 2026-09-08 · checked 2026-11-09 15:47 UTC